TY - JOUR
T1 - SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document
T2 - Online resources and useful tools - a compass in the land of biomarker discovery
AU - Bedognetti, Davide
AU - Balwit, James M.
AU - Wang, Ena
AU - Disis, Mary L.
AU - Britten, Cedrik M.
AU - Delogu, Lucia G.
AU - Tomei, Sara
AU - Fox, Bernard A.
AU - Gajewski, Thomas F.
AU - Marincola, Francesco M.
AU - Butterfield, Lisa H.
N1 - Funding Information:
The authors wish to acknowledge the members of the SITC/iSBTc Taskforce on Immunotherapy Biomarkers, Working Group 2 who reviewed these resources as part of the planning for the Symposium on Immuno-Oncology Biomarkers, 2010 and Beyond. This working group includes: Francesco Marincola, Peter P. Lee, Damien Chaussabel, George Coukos, Bernard Fox, John Kirkwood, Leif Håkansson, Michele Maio, Antoni Ribas, Dolores Schendel, Barbara Selinger, Senthamil Selvan, Wenru Song, Howard Streicher, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Xifeng Wu, Ben Zeskind, Yingdong Zhao. The authors also wish to acknowledge all colleagues who reviewed and commented on previous versions of this document, including: Pietro Blandini, Enrico Lugli, Stefania Santamaria, Tim Greten, Sylvia Janetzki, Janet Siebert, Wenji Zhang and Gabriele Zoppoli. Davide Bedognetti is a participant in the NIH Graduate Partnership Program and a graduate student at University of Genoa. Davide Bedognetti’s fellowship is supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology (2011 Young Investigator Award).
PY - 2011/9/19
Y1 - 2011/9/19
N2 - Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are durable, dramatically extending survival. Extensive research efforts are being made to identify and validate biomarkers that can help identify subsets of cancer patients that will benefit most from these novel immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were identified by experts in the field who are actively pursuing research in biomarker identification and validation. This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies.
AB - Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are durable, dramatically extending survival. Extensive research efforts are being made to identify and validate biomarkers that can help identify subsets of cancer patients that will benefit most from these novel immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were identified by experts in the field who are actively pursuing research in biomarker identification and validation. This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=80052850127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052850127&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-9-155
DO - 10.1186/1479-5876-9-155
M3 - Review article
C2 - 21929757
AN - SCOPUS:80052850127
SN - 1479-5876
VL - 9
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 155
ER -